{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T10:37:18Z","timestamp":1783161438093,"version":"3.54.6"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:00:00Z","timestamp":1642204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:00:00Z","timestamp":1642204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["SB\/S2\/RJN-132\/20\/5"],"award-info":[{"award-number":["SB\/S2\/RJN-132\/20\/5"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001843","name":"Science and Engineering Research Board","doi-asserted-by":"publisher","award":["EMR\/2017\/001637"],"award-info":[{"award-number":["EMR\/2017\/001637"]}],"id":[{"id":"10.13039\/501100001843","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s11033-021-07063-9","type":"journal-article","created":{"date-parts":[[2022,1,15]],"date-time":"2022-01-15T00:04:35Z","timestamp":1642205075000},"page":"2519-2530","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Kinases and therapeutics in pathogen mediated gastric cancer"],"prefix":"10.1007","volume":"49","author":[{"given":"Charu","family":"Sonkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nidhi","family":"Varshney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siva","family":"Koganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9698-4547","authenticated-orcid":false,"given":"Hem Chandra","family":"Jha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,1,15]]},"reference":[{"key":"7063_CR1","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3390\/cancers10030063","volume":"10","author":"J Cicenas","year":"2018","unstructured":"Cicenas J, Zalyte E, Bairoch A, Gaudet P (2018) Kinases and cancer. Cancers (Basel) 10:63","journal-title":"Cancers (Basel)"},{"key":"7063_CR2","doi-asserted-by":"crossref","first-page":"591","DOI":"10.3390\/toxins11100591","volume":"11","author":"BE Chichirau","year":"2019","unstructured":"Chichirau BE, Diechler S, Posselt G, Wessler S (2019) Tyrosine kinases in Helicobacter pylori infections and gastric cancer. Toxins (Basel). 11:591","journal-title":"Toxins (Basel)."},{"key":"7063_CR3","doi-asserted-by":"crossref","first-page":"e298","DOI":"10.1038\/oncsis.2016.80","volume":"6","author":"M Kamran","year":"2017","unstructured":"Kamran M, Long Z-J, Xu D, Lv S-S, Liu B, Wang C-L et al (2017) Aurora kinase A regulates survivin stability through targeting FBXL7 in gastric cancer drug resistance and prognosis. Oncogenesis 6:e298\u2013e298","journal-title":"Oncogenesis"},{"key":"7063_CR4","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.cgh.2019.07.045","volume":"18","author":"AP Thrift","year":"2020","unstructured":"Thrift AP, El-Serag HB (2020) Burden of gastric cancer. Clin Gastroenterol Hepatol 18:534\u2013542","journal-title":"Clin Gastroenterol Hepatol"},{"key":"7063_CR5","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2147\/CMAR.S149619","volume":"10","author":"R Sitarz","year":"2018","unstructured":"Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, Polkowski WP (2018) Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Manag Res 10:239\u2013248","journal-title":"Cancer Manag Res"},{"key":"7063_CR6","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/3456264","author":"S Singh","year":"2017","unstructured":"Singh S, Jha HC (2017) Status of Epstein-Barr virus coinfection with Helicobacter pylori in gastric cancer. J Oncol. https:\/\/doi.org\/10.1155\/2017\/3456264","journal-title":"J Oncol"},{"key":"7063_CR7","first-page":"59","volume":"7","author":"P Correa","year":"2011","unstructured":"Correa P, Piazuelo MB (2011) Helicobacter pylori infection and gastric adenocarcinoma. US Gastroenterol Hepatol Rev 7:59","journal-title":"US Gastroenterol Hepatol Rev"},{"key":"7063_CR8","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41417-019-0125-7","volume":"27","author":"D Liu","year":"2020","unstructured":"Liu D, Ma X, Yang F, Xiao D, Jia Y, Wang Y (2020) Discovery and validation of methylated-differentially expressed genes in Helicobacter pylori-induced gastric cancer. Cancer Gene Ther 27:473\u2013485","journal-title":"Cancer Gene Ther"},{"key":"7063_CR9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3389\/fmicb.2018.00005","volume":"9","author":"P D\u00edaz","year":"2018","unstructured":"D\u00edaz P, Valenzuela Valderrama M, Bravo J, Quest AFG (2018) Helicobacter pylori and gastric cancer: adaptive cellular mechanisms involved in disease progression. Front Microbiol 9:5","journal-title":"Front Microbiol"},{"key":"7063_CR10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s12866-020-01728-4","volume":"20","author":"D Kashyap","year":"2020","unstructured":"Kashyap D, Baral B, Verma TP, Sonkar C, Chatterji D, Jain AK et al (2020) Oral rinses in growth inhibition and treatment of Helicobacter pylori infection. BMC Microbiol 20:45","journal-title":"BMC Microbiol"},{"key":"7063_CR11","doi-asserted-by":"crossref","first-page":"e01332","DOI":"10.1128\/mBio.01332-19","volume":"10","author":"MR Eichelberg","year":"2019","unstructured":"Eichelberg MR, Welch R, Guidry JT, Ali A, Ohashi M, Makielski KR et al (2019) Epstein-Barr virus infection promotes epithelial cell growth by attenuating differentiation-dependent exit from the cell cycle. MBio 10:e01332","journal-title":"MBio"},{"key":"7063_CR12","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/onc.2016.187","volume":"36","author":"J Yu","year":"2017","unstructured":"Yu J, Liang Q, Wang J, Wang K, Gao J, Zhang J et al (2017) REC8 functions as a tumor suppressor and is epigenetically downregulated in gastric cancer, especially in EBV-positive subtype. Oncogene 36:182\u2013193","journal-title":"Oncogene"},{"key":"7063_CR13","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.diagmicrobio.2018.04.015","volume":"92","author":"S Fattahi","year":"2018","unstructured":"Fattahi S, Nikbakhsh N, Taheri H, Ghadami E, Kosari-Monfared M, Amirbozorgi G et al (2018) Prevalence of multiple infections and the risk of gastric adenocarcinoma development at earlier age. Diagn Microbiol Infect Dis 92:62\u201368","journal-title":"Diagn Microbiol Infect Dis"},{"key":"7063_CR14","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1126\/science.1080857","volume":"299","author":"D Falush","year":"2003","unstructured":"Falush D (2003) Traces of human migrations in Helicobacter pylori populations. Science 299:1582\u20131585","journal-title":"Science"},{"key":"7063_CR15","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJM199110173251604","volume":"325","author":"A Nomura","year":"1991","unstructured":"Nomura A, Stemmermann GN, Chyou P-H, Kato I, Perez-Perez GI, Blaser MJ (1991) Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med 325:1132\u20131136","journal-title":"N Engl J Med"},{"key":"7063_CR16","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.3748\/wjg.v23.i9.1521","volume":"23","author":"M Chmiela","year":"2017","unstructured":"Chmiela M, Karwowska Z, Gonciarz W, Allushi B, St\u0105czek P (2017) Host pathogen interactions in Helicobacter pylori related gastric cancer. World J Gastroenterol 23:1521\u20131540","journal-title":"World J Gastroenterol"},{"key":"7063_CR17","doi-asserted-by":"publisher","DOI":"10.1155\/2019\/1271872","author":"N Y\u0131lmaz","year":"2019","unstructured":"Y\u0131lmaz N, Koruk-\u00d6zer M (2019) The prevalence of Helicobacter pylori babA, homB, aspA, and sabA genes and its relationship with clinical outcomes in Turkey. Can J Gastroenterol Hepatol. https:\/\/doi.org\/10.1155\/2019\/1271872","journal-title":"Can J Gastroenterol Hepatol"},{"key":"7063_CR18","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1126\/science.279.5349.373","volume":"279","author":"D Ilver","year":"1998","unstructured":"Ilver D, Arnqvist A, \u00d6gren J, Frick I-M, Kersulyte D, Incecik ET et al (1998) Helicobacter pylori adhesin binding fucosylated Histo-Blood Group antigens revealed by retagging. Science 279:373\u2013377","journal-title":"Science"},{"key":"7063_CR19","doi-asserted-by":"crossref","first-page":"46499","DOI":"10.1038\/srep46499","volume":"7","author":"ME Kable","year":"2017","unstructured":"Kable ME, Hansen LM, Styer CM, Deck SL, Rakhimova O, Shevtsova A et al (2017) Host determinants of expression of the Helicobacter pylori BabA adhesin. Sci Rep 7:46499","journal-title":"Sci Rep"},{"key":"7063_CR20","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1046\/j.1365-2958.1997.5881952.x","volume":"26","author":"MD Bernard","year":"1997","unstructured":"Bernard MD, Arico B, Papini E, Rizzuto R, Grandi G, Rappuoli R et al (1997) Helicobacter pylori toxin VacA induces vacuole formation by acting in the cell cytosol. Mol Microbiol 26:665\u2013674","journal-title":"Mol Microbiol"},{"key":"7063_CR21","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/toxins8060173","volume":"8","author":"NJ Foegeding","year":"2016","unstructured":"Foegeding NJ, Caston RR, McClain MS, Ohi MD, Cover TL (2016) An overview of Helicobacter pylori VacA toxin biology. Toxins 8:173","journal-title":"Toxins"},{"key":"7063_CR22","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41419-017-0042-3","volume":"8","author":"P Zhu","year":"2017","unstructured":"Zhu P, Xue J, Zhang Z, Jia Y, Tong Y, Han D et al (2017) Helicobacter pylori VacA induces autophagic cell death in gastric epithelial cells via the endoplasmic reticulum stress pathway. Cell Death Dis 8:1\u201312","journal-title":"Cell Death Dis"},{"key":"7063_CR23","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1038\/nrmicro1095","volume":"3","author":"TL Cover","year":"2005","unstructured":"Cover TL, Blanke SR (2005) Helicobacter pylori VacA, a paradigm for toxin multifunctionality. Nat Rev Microbiol 3:320\u2013332","journal-title":"Nat Rev Microbiol"},{"key":"7063_CR24","doi-asserted-by":"crossref","first-page":"4870","DOI":"10.3748\/wjg.v25.i33.4870","volume":"25","author":"A \u0160terbenc","year":"2019","unstructured":"\u0160terbenc A, Jarc E, Poljak M, Homan M (2019) Helicobacter pylori virulence genes. World J Gastroenterol 25:4870\u20134884","journal-title":"World J Gastroenterol"},{"key":"7063_CR25","doi-asserted-by":"crossref","first-page":"D824","DOI":"10.1093\/nar\/gkn832","volume":"37","author":"CJ Richardson","year":"2009","unstructured":"Richardson CJ, Gao Q, Mitsopoulous C, Zvelebil M, Pearl LH, Pearl FMG (2009) MoKCa database\u2014mutations of kinases in cancer. Nucleic Acids Res 37:D824\u2013D831","journal-title":"Nucleic Acids Res"},{"key":"7063_CR26","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/38792","volume":"389","author":"J-F Tomb","year":"1997","unstructured":"Tomb J-F, White O, Kerlavage AR, Clayton RA, Sutton GG, Fleischmann RD et al (1997) Erratum: the complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 389:412\u2013412","journal-title":"Nature"},{"key":"7063_CR27","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1007\/s001099900067","volume":"77","author":"RA Alm","year":"1999","unstructured":"Alm RA, Trust TJ (1999) Analysis of the genetic diversity of Helicobacter pylori: the tale of two genomes. J Mol Med 77:834\u2013846","journal-title":"J Mol Med"},{"key":"7063_CR28","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.3892\/or.2016.5145","volume":"36","author":"S-Y Chen","year":"2016","unstructured":"Chen S-Y, Zhang R-G, Duan G-C (2016) Pathogenic mechanisms of the oncoprotein CagA in H. pylori-induced gastric cancer (Review). Oncol Rep 36:3087\u20133094","journal-title":"Oncol Rep"},{"key":"7063_CR29","doi-asserted-by":"crossref","first-page":"7113","DOI":"10.1038\/s41598-017-07193-w","volume":"7","author":"X Liu","year":"2017","unstructured":"Liu X, Ji Q, Zhang C, Liu X, Liu Y, Liu N et al (2017) miR-30a acts as a tumor suppressor by double-targeting COX-2 and BCL9 in H. pylori gastric cancer models. Sci Rep 7:7113","journal-title":"Sci Rep"},{"key":"7063_CR30","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1186\/s12885-016-2351-9","volume":"16","author":"N Liu","year":"2016","unstructured":"Liu N, Zhou N, Chai N, Liu X, Jiang H, Wu Q et al (2016) Helicobacter pylori promotes angiogenesis depending on Wnt\/beta-catenin-mediated vascular endothelial growth factor via the cyclooxygenase-2 pathway in gastric cancer. BMC Cancer 16:321","journal-title":"BMC Cancer"},{"key":"7063_CR31","doi-asserted-by":"crossref","first-page":"e12530","DOI":"10.1111\/hel.12530","volume":"23","author":"Y Hu","year":"2018","unstructured":"Hu Y, He C, Liu J-P, Li N-S, Peng C, Yang-Ou Y-B et al (2018) Analysis of key genes and signaling pathways involved in Helicobacter pylori-associated gastric cancer based on The Cancer Genome Atlas database and RNA sequencing data. Helicobacter 23:e12530","journal-title":"Helicobacter"},{"key":"7063_CR32","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s10120-018-0880-4","volume":"22","author":"S Sasaki","year":"2019","unstructured":"Sasaki S, Nishikawa J, Sakai K, Iizasa H, Yoshiyama H, Yanagihara M et al (2019) EBV-associated gastric cancer evades T-cell immunity by PD-1\/PD-L1 interactions. Gastric Cancer 22:486\u2013496","journal-title":"Gastric Cancer"},{"key":"7063_CR33","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.3389\/fmicb.2016.01602","volume":"7","author":"HC Jha","year":"2016","unstructured":"Jha HC, Pei Y, Robertson ES (2016) Epstein-Barr virus: diseases linked to infection and transformation. Front Microbiol 7:1602. https:\/\/doi.org\/10.3389\/fmicb.2016.01602","journal-title":"Front Microbiol"},{"key":"7063_CR34","volume-title":"Human herpesviruses: biology, therapy, and immunoprophylaxis","author":"LS Young","year":"2007","unstructured":"Young LS, Arrand JR, Murray PG (2007) EBV gene expression and regulation. In: Arvin A, Campadelli-Fiume G, Mocarski E, Moore PS, Roizman B, Whitley R et al (eds) Human herpesviruses: biology, therapy, and immunoprophylaxis. Cambridge University Press, Cambridge"},{"key":"7063_CR35","doi-asserted-by":"crossref","first-page":"5788","DOI":"10.18632\/oncotarget.3310","volume":"6","author":"HC Jha","year":"2015","unstructured":"Jha HC, Yang K, El-Naccache DW, Sun Z, Robertson ES (2015) EBNA3C regulates p53 through induction of Aurora kinase B. Oncotarget Impact J 6:5788\u20135803","journal-title":"Oncotarget Impact J"},{"key":"7063_CR36","doi-asserted-by":"crossref","first-page":"12121","DOI":"10.1128\/JVI.02379-13","volume":"87","author":"HC Jha","year":"2013","unstructured":"Jha HC, Lu J, Saha A, Cai Q, Banerjee S, Prasad MAJ et al (2013) EBNA3C-mediated regulation of aurora kinase B contributes to Epstein\u2013Barr virus-induced B-cell proliferation through modulation of the activities of the retinoblastoma protein and apoptotic caspases. J Virol 87:12121\u201312138","journal-title":"J Virol"},{"key":"7063_CR37","doi-asserted-by":"crossref","first-page":"38399","DOI":"10.18632\/oncotarget.16417","volume":"8","author":"R Zhang","year":"2017","unstructured":"Zhang R, Strong MJ, Baddoo M, Lin Z, Wang Y-P, Flemington EK et al (2017) Interaction of Epstein\u2013Barr virus genes with human gastric carcinoma transcriptome. Oncotarget Impact J 8:38399\u201338412","journal-title":"Oncotarget Impact J"},{"key":"7063_CR38","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/j.1440-1827.2010.02533.x","volume":"60","author":"M Fukayama","year":"2010","unstructured":"Fukayama M (2010) Epstein-Barr virus and gastric carcinoma. Pathol Int 60:337\u2013350","journal-title":"Pathol Int"},{"key":"7063_CR39","doi-asserted-by":"crossref","first-page":"4003","DOI":"10.21873\/anticanres.13555","volume":"39","author":"BW Kang","year":"2019","unstructured":"Kang BW, Baek DW, Kang H, Baek JH, Kim JG (2019) Novel therapeutic approaches for Epstein\u2013Barr virus associated gastric cancer. Anticancer Res 39:4003\u20134010","journal-title":"Anticancer Res"},{"key":"7063_CR40","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"AJ Bass","year":"2014","unstructured":"Bass AJ, Thorsson V, Shmulevich I, Reynolds SM, Miller M, Bernard B et al (2014) Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513:202\u2013209","journal-title":"Nature"},{"key":"7063_CR41","doi-asserted-by":"crossref","first-page":"3916","DOI":"10.3748\/wjg.v20.i14.3916","volume":"20","author":"K Matsusaka","year":"2014","unstructured":"Matsusaka K, Funata S, Fukayama M, Kaneda A (2014) DNA methylation in gastric cancer, related to Helicobacter pylori and Epstein\u2013Barr virus. World J Gastroenterol 20:3916\u20133926","journal-title":"World J Gastroenterol"},{"key":"7063_CR42","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1155\/2010\/453764","volume":"33","author":"H Geddert","year":"2010","unstructured":"Geddert H, Hausen AZ, Gabbert HE, Sarbia M (2010) EBV-infection in cardiac and non-cardiac gastric adenocarcinomas is associated with promoter methylation of p16, p14 and APC, but not hMLH1. Anal Cell Pathol 33:143\u2013149","journal-title":"Anal Cell Pathol"},{"key":"7063_CR43","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ctrv.2018.03.006","volume":"66","author":"M Naseem","year":"2018","unstructured":"Naseem M, Barzi A, Brezden-Masley C, Puccini A, Berger MD, Tokunaga R et al (2018) Outlooks on Epstein\u2013Barr virus associated gastric cancer. Cancer Treat Rev 66:15\u201322","journal-title":"Cancer Treat Rev"},{"key":"7063_CR44","first-page":"13","volume":"6","author":"CN Miliotis","year":"2020","unstructured":"Miliotis CN, Slack FJ (2020) Multi-layered control of PD-L1 expression in Epstein\u2013Barr virus-associated gastric cancer. J Cancer Meta Treat 6:13","journal-title":"J Cancer Meta Treat"},{"key":"7063_CR45","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1186\/s12885-020-07377-0","volume":"20","author":"C Sonkar","year":"2020","unstructured":"Sonkar C, Verma T, Chatterji D, Jain AK, Jha HC (2020) Status of kinases in Epstein\u2013Barr virus and Helicobacter pylori coinfection in gastric cancer cells. BMC Cancer 20:925","journal-title":"BMC Cancer"},{"key":"7063_CR46","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01183-10","author":"N Sivachandran","year":"2020","unstructured":"Sivachandran N et al (2020) Epstein\u2013Barr nuclear antigen 1 hijacks the host kinase CK2 to disrupt PML nuclear bodies. J Virol. https:\/\/doi.org\/10.1128\/JVI.01183-10","journal-title":"J Virol"},{"key":"7063_CR47","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1128\/JVI.78.4.1697-1705.2004","volume":"78","author":"M Fukuda","year":"2004","unstructured":"Fukuda M, Longnecker R (2004) Latent membrane protein 2A inhibits transforming growth factor-\u03b21-induced apoptosis through the phosphatidylinositol 3-Kinase\/Akt pathway. J Virol 78:1697\u20131705","journal-title":"J Virol"},{"key":"7063_CR48","doi-asserted-by":"crossref","first-page":"9299","DOI":"10.1128\/JVI.00537-07","volume":"81","author":"M Fukuda","year":"2007","unstructured":"Fukuda M, Longnecker R (2007) Epstein\u2013Barr virus latent membrane protein 2A mediates transformation through constitutive activation of the Ras\/PI3-K\/Akt pathway. J Virol 81:9299\u20139306","journal-title":"J Virol"},{"key":"7063_CR49","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1158\/0008-5472.CAN-07-3027","volume":"68","author":"R Hino","year":"2008","unstructured":"Hino R, Uozaki H, Inoue Y, Shintani Y, Ushiku T, Sakatani T et al (2008) Survival advantage of EBV-associated gastric carcinoma: survivin up-regulation by viral latent membrane protein 2A. Cancer Res 68:1427\u20131435","journal-title":"Cancer Res"},{"key":"7063_CR50","doi-asserted-by":"crossref","first-page":"197735","DOI":"10.1016\/j.virusres.2019.197735","volume":"272","author":"Y-F Qi","year":"2019","unstructured":"Qi Y-F, Liu M, Zhang Y, Liu W, Xiao H, Luo B (2019) EBV down-regulates COX-2 expression via TRAF2 and ERK signal pathway in EBV-associated gastric cancer. Virus Res 272:197735","journal-title":"Virus Res"},{"key":"7063_CR51","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3390\/pathogens9020104","volume":"9","author":"R D\u00e1vila-Collado","year":"2020","unstructured":"D\u00e1vila-Collado R, Jarqu\u00edn-Dur\u00e1n O, Dong LT, Espinoza JL (2020) Epstein-Barr virus and Helicobacter pylori co-infection in non-malignant gastroduodenal disorders. Pathogens 9:104","journal-title":"Pathogens"},{"key":"7063_CR52","doi-asserted-by":"crossref","first-page":"e00649","DOI":"10.1128\/mBio.00649-18","volume":"9","author":"S Pandey","year":"2018","unstructured":"Pandey S, Jha HC, Shukla SK, Shirley MK, Robertson ES (2018) Epigenetic regulation of tumor suppressors by Helicobacter pylori enhances EBV-induced proliferation of gastric epithelial cells. MBio 9:e00649","journal-title":"MBio"},{"key":"7063_CR53","doi-asserted-by":"crossref","first-page":"e62850","DOI":"10.1371\/journal.pone.0062850","volume":"8","author":"MG C\u00e1rdenas-Mondrag\u00f3n","year":"2013","unstructured":"C\u00e1rdenas-Mondrag\u00f3n MG, Carre\u00f3n-Talavera R, Camorlinga-Ponce M, Gomez-Delgado A, Torres J, Fuentes-Panan\u00e1 EM (2013) Epstein Barr virus and Helicobacter pylori co-infection are positively associated with severe gastritis in pediatric patients. PLoS ONE 8:e62850","journal-title":"PLoS ONE"},{"key":"7063_CR54","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/s12964-014-0046-x","volume":"12","author":"CF Mohr","year":"2014","unstructured":"Mohr CF, Kalmer M, Gross C, Mann MC, Sterz KR, Kieser A et al (2014) The tumor marker Fascin is induced by the Epstein\u2013Barr virus-encoded oncoprotein LMP1 via NF-\u03baB in lymphocytes and contributes to their invasive migration. Cell Commun Signal 12:46","journal-title":"Cell Commun Signal"},{"key":"7063_CR55","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1128\/JVI.01410-15","volume":"90","author":"X Liu","year":"2016","unstructured":"Liu X, Cohen JI (2016) Epstein\u2013Barr virus (EBV) tegument protein bgLF2 promotes EBV reactivation through activation of the p38 mitogen-activated protein kinase. J Virol 90:1129\u20131138","journal-title":"J Virol"},{"key":"7063_CR56","doi-asserted-by":"crossref","first-page":"e0183324","DOI":"10.1371\/journal.pone.0183324","volume":"12","author":"MG Pena-Ponce","year":"2017","unstructured":"Pena-Ponce MG, Jimenez MT, Hansen LM, Solnick JV, Miller LA (2017) The Helicobacter pylori type IV secretion system promotes IL-8 synthesis in a model of pediatric airway epithelium via p38 MAP kinase. PLoS ONE 12:e0183324","journal-title":"PLoS ONE"},{"key":"7063_CR57","doi-asserted-by":"crossref","first-page":"647","DOI":"10.3349\/ymj.2016.57.3.647","volume":"57","author":"E Byun","year":"2016","unstructured":"Byun E, Park B, Lim JW, Kim H (2016) Activation of NF-\u03baB and AP-1 mediates hyperproliferation by inducing \u03b2-catenin and c-Myc in Helicobacter pylori-infected gastric epithelial cells. Yonsei Med J 57:647\u2013651","journal-title":"Yonsei Med J"},{"key":"7063_CR58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nmicrobiol.2016.26","volume":"1","author":"P Saju","year":"2016","unstructured":"Saju P, Murata-Kamiya N, Hayashi T, Senda Y, Nagase L, Noda S et al (2016) Host SHP1 phosphatase antagonizes Helicobacter pylori CagA and can be downregulated by Epstein\u2013Barr virus. Nat Microbiol 1:1\u20138","journal-title":"Nat Microbiol"},{"key":"7063_CR59","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jcv.2007.11.014","volume":"41","author":"J Sinclair","year":"2008","unstructured":"Sinclair J (2008) Human cytomegalovirus: latency and reactivation in the myeloid lineage. J Clin Virol 41:180\u2013185","journal-title":"J Clin Virol"},{"key":"7063_CR60","doi-asserted-by":"crossref","first-page":"883","DOI":"10.2217\/fmb.10.58","volume":"5","author":"B Slobedman","year":"2010","unstructured":"Slobedman B, Cao JZ, Avdic S, Webster B, McAllery S, Cheung AK et al (2010) Human cytomegalovirus latent infection and associated viral gene expression. Fut Microbiol 5:883\u2013900","journal-title":"Fut Microbiol"},{"key":"7063_CR61","doi-asserted-by":"crossref","first-page":"e14124","DOI":"10.1097\/MD.0000000000014124","volume":"98","author":"O Del Moral-Hern\u00e1ndez","year":"2019","unstructured":"Del Moral-Hern\u00e1ndez O, Casta\u00f1\u00f3n-S\u00e1nchez CA, Reyes-Navarrete S, Mart\u00ednez-Carrillo DN, Betancourt-Linares R, Jim\u00e9nez-Wences H et al (2019) Multiple infections by EBV, HCMV and Helicobacter pylori are highly frequent in patients with chronic gastritis and gastric cancer from Southwest Mexico: an observational study. Medicine 98:e14124","journal-title":"Medicine"},{"key":"7063_CR62","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.virusres.2010.10.026","volume":"157","author":"L Soroceanu","year":"2011","unstructured":"Soroceanu L, Cobbs CS (2011) Is HCMV a tumor promoter? Virus Res 157:193\u2013203","journal-title":"Virus Res"},{"key":"7063_CR63","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.diagmicrobio.2017.02.001","volume":"88","author":"L Zhang","year":"2017","unstructured":"Zhang L, Guo G, Xu J, Sun X, Chen W, Jin J et al (2017) Human cytomegalovirus detection in gastric cancer and its possible association with lymphatic metastasis. Diagn Microbiol Infect Dis 88:62\u201368","journal-title":"Diagn Microbiol Infect Dis"},{"key":"7063_CR64","doi-asserted-by":"crossref","first-page":"22369","DOI":"10.1073\/pnas.0908787106","volume":"106","author":"G Chan","year":"2009","unstructured":"Chan G, Nogalski MT, Yurochko AD (2009) Activation of EGFR on monocytes is required for human cytomegalovirus entry and mediates cellular motility. PNAS Natl Acad Sci 106:22369\u201322374","journal-title":"PNAS Natl Acad Sci"},{"key":"7063_CR65","doi-asserted-by":"crossref","first-page":"e1006281","DOI":"10.1371\/journal.ppat.1006281","volume":"13","author":"Y Wu","year":"2017","unstructured":"Wu Y, Prager A, Boos S, Resch M, Brizic I, Mach M et al (2017) Human cytomegalovirus glycoprotein complex gH\/gL\/gO uses PDGFR-\u03b1 as a key for entry. PLoS Pathog 13:e1006281","journal-title":"PLoS Pathog"},{"key":"7063_CR66","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2217\/fvl-2019-0117","volume":"15","author":"A Mohebbi","year":"2020","unstructured":"Mohebbi A, Mamizadeh Z, Bagheri H, Sharifnezhad F, Tabarraei A, Yazdi M (2020) Prevalent latent human cytomegalovirus genotype b2 in biopsy samples of gastric cancer. Future Virol Future Med 15:71\u201378","journal-title":"Future Virol Future Med"},{"key":"7063_CR67","doi-asserted-by":"crossref","first-page":"9261","DOI":"10.1002\/jcp.27030","volume":"233","author":"S Fattahi","year":"2018","unstructured":"Fattahi S, Kosari-Monfared M, Ghadami E, Golpour M, Khodadadi P, Ghasemiyan M et al (2018) Infection-associated epigenetic alterations in gastric cancer: new insight in cancer therapy. J Cell Physiol 233:9261\u20139270","journal-title":"J Cell Physiol"},{"key":"7063_CR68","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1002\/jcp.27106","volume":"234","author":"M Kosari-Monfared","year":"2019","unstructured":"Kosari-Monfared M, Nikbakhsh N, Fattahi S, Ghadami E, Ranaei M, Taheri H et al (2019) CTNNBIP1 downregulation is associated with tumor grade and viral infections in gastric adenocarcinoma. J Cell Physiol 234:2895\u20132904","journal-title":"J Cell Physiol"},{"key":"7063_CR69","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-020-01749-z","author":"L Shi","year":"2020","unstructured":"Shi L, Fan B, Chen D, Guo C, Xiang H, Nie Y et al (2020) Human cytomegalovirus protein UL136 activates the IL-6, STAT3 signal through MiR-138 and MiR-34c in gastric cancer cells. Int J Clin Oncol. https:\/\/doi.org\/10.1007\/s10147-020-01749-z","journal-title":"Int J Clin Oncol"},{"key":"7063_CR70","doi-asserted-by":"crossref","first-page":"5630","DOI":"10.18632\/oncotarget.6800","volume":"7","author":"W Chen","year":"2015","unstructured":"Chen W, Lin K, Zhang L, Guo G, Sun X, Chen J et al (2015) The cytomegalovirus protein UL138 induces apoptosis of gastric cancer cells by binding to heat shock protein 70. Oncotarget Impact J 7:5630\u20135645","journal-title":"Oncotarget Impact J"},{"key":"7063_CR71","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/7973568","author":"L Meng","year":"2020","unstructured":"Meng L, Ding L, Yu Y, Li W (2020) JAK3 and TYK2 serve as prognostic biomarkers and are associated with immune infiltration in stomach adenocarcinoma. BioMed Res Int. https:\/\/doi.org\/10.1155\/2020\/7973568","journal-title":"BioMed Res Int"},{"key":"7063_CR72","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.3390\/cancers11111728","volume":"11","author":"K W\u00f6ss","year":"2019","unstructured":"W\u00f6ss K, Simonovi\u0107 N, Strobl B, Macho-Maschler S, M\u00fcller M (2019) TYK2: an upstream kinase of STATs in cancer. Cancers 11:1728","journal-title":"Cancers"},{"key":"7063_CR73","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.coph.2015.05.016","volume":"23","author":"TA Yap","year":"2015","unstructured":"Yap TA, Bjerke L, Clarke PA, Workman P (2015) Drugging PI3K in cancer: refining targets and therapeutic strategies. Curr Opin Pharmacol 23:98\u2013107","journal-title":"Curr Opin Pharmacol"},{"key":"7063_CR74","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/ijc.22442","volume":"120","author":"SA Lang","year":"2007","unstructured":"Lang SA, Gaumann A, Koehl GE, Seidel U, Bataille F, Klein D et al (2007) Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model. Int J Cancer 120:1803\u20131810","journal-title":"Int J Cancer"},{"key":"7063_CR75","unstructured":"Genentech, Inc (2020) A randomized, phase II, placebo-controlled study of Ipatasertib (GDC-0068), an inhibitor to Akt, in combination with fluoropyrimidine plus oxaliplatin in patients with locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma. clinicaltrials.gov. Report No.: NCT01896531. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01896531"},{"key":"7063_CR76","unstructured":"Novartis Pharmaceuticals (2020) A phase IB, multicenter, open-label dose escalation study of the PI3K inhibitor BYL719 in combination with the HSP90 inhibitor AUY922 in patients with advanced or metastatic gastric cancer carrying a molecular alteration of PIK3CA or an amplification of HER2. clinicaltrials.gov. Report No.: NCT01613950. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01613950"},{"key":"7063_CR77","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.critrevonc.2016.02.007","volume":"100","author":"YLE Ang","year":"2016","unstructured":"Ang YLE, Yong WP, Tan P (2016) Translating gastric cancer genomics into targeted therapies. Crit Rev Oncol Hematol 100:141\u2013146","journal-title":"Crit Rev Oncol Hematol"},{"key":"7063_CR78","unstructured":"Amgen (2016) A Phase 1, first-in-human study evaluating the safety, tolerability, and pharmacokinetics of AMG 337 in adult subjects with advanced solid tumors. clinicaltrials.gov. Report No.: NCT01253707. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01253707"},{"key":"7063_CR79","unstructured":"Amgen (2017) A multicenter, Phase 2, single arm, two cohort study evaluating the efficacy, safety, and pharmacokinetics of AMG337 in subjects with MET amplified gastric\/gastroesophageal junction\/esophageal adenocarcinoma or other MET amplified solid tumors. clinicaltrials.gov. Report No.: NCT02016534. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02016534"},{"key":"7063_CR80","unstructured":"C-Met (2020) Inhibitor AMG 337, oxaliplatin, leucovorin calcium, and fluorouracil in treating patients with advanced stomach or esophageal cancer\u2014full text view. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02344810"},{"key":"7063_CR81","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.3390\/ijms21082893","volume":"21","author":"L Magnelli","year":"2020","unstructured":"Magnelli L, Schiavone N, Staderini F, Biagioni A, Papucci L (2020) MAP kinases pathways in gastric cancer. Int J Mol Sci 21:2893","journal-title":"Int J Mol Sci"},{"key":"7063_CR82","doi-asserted-by":"crossref","first-page":"638","DOI":"10.7150\/jca.38536","volume":"11","author":"Y Cui","year":"2020","unstructured":"Cui Y, Yu S, Zhu M, Cheng X, Yu Y, Tang Z et al (2020) Identifying predictive factors of recurrence after radical resection in gastric cancer by RNA immune-oncology panel. J Cancer 11:638\u2013647","journal-title":"J Cancer"},{"key":"7063_CR83","doi-asserted-by":"crossref","first-page":"731","DOI":"10.3390\/cancers12030731","volume":"12","author":"C Pottier","year":"2020","unstructured":"Pottier C, Fresnais M, Gilon M, J\u00e9rusalem G, Longuesp\u00e9e R, Sounni NE (2020) Tyrosine kinase inhibitors in cancer: breakthrough and challenges of targeted therapy. Cancers 12:731","journal-title":"Cancers"},{"key":"7063_CR84","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1758834015616935","volume":"8","author":"E Fontana","year":"2016","unstructured":"Fontana E, Smyth EC (2016) Novel targets in the treatment of advanced gastric cancer: a perspective review. Ther Adv Med Oncol 8:113\u2013125","journal-title":"Ther Adv Med Oncol"},{"key":"7063_CR85","doi-asserted-by":"crossref","first-page":"5680","DOI":"10.1038\/sj.onc.1203924","volume":"19","author":"W Lin","year":"2000","unstructured":"Lin W, Kao H-W, Robinson D, Kung H-J, Wu C-W, Chen H-C (2000) Tyrosine kinases and gastric cancer. Oncogene 19:5680\u20135689","journal-title":"Oncogene"},{"key":"7063_CR86","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.1182\/blood-2007-12-129718","volume":"112","author":"EA Nelson","year":"2008","unstructured":"Nelson EA, Walker SR, Kepich A, Gashin LB, Hideshima T, Ikeda H et al (2008) Nifuroxazide inhibits survival of multiple myeloma cells by directly inhibiting STAT3. Blood 112:5095\u20135102","journal-title":"Blood"},{"key":"7063_CR87","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s11864-015-0331-y","volume":"16","author":"Y Sunakawa","year":"2015","unstructured":"Sunakawa Y, Lenz H-J (2015) Molecular classification of gastric adenocarcinoma: translating new insights from the cancer genome atlas research network. Curr Treat Options in Oncol 16:17","journal-title":"Curr Treat Options in Oncol"},{"key":"7063_CR88","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s11427-010-0082-8","volume":"53","author":"S Li","year":"2010","unstructured":"Li S, Du H, Wang Z, Zhou L, Zhao X, Zeng Y (2010) Meta-analysis of the relationship between Epstein\u2013Barr virus infection and clinicopathological features of patients with gastric carcinoma. Sci China Life Sci 53:524\u2013530","journal-title":"Sci China Life Sci"},{"key":"7063_CR89","doi-asserted-by":"crossref","first-page":"e953203","DOI":"10.1155\/2014\/953203","volume":"2014","author":"M Gryko","year":"2014","unstructured":"Gryko M, Pryczynicz A, Zareba K, K\u0119dra B, Kemona A, Guzi\u0144ska-Ustymowicz K (2014) The expression of Bcl-2 and BID in gastric cancer cells. J Immunol Res 2014:e953203","journal-title":"J Immunol Res"},{"key":"7063_CR90","doi-asserted-by":"crossref","first-page":"3965","DOI":"10.1128\/IAI.69.6.3965-3971.2001","volume":"69","author":"Y Hirata","year":"2001","unstructured":"Hirata Y, Maeda S, Mitsuno Y, Akanuma M, Yamaji Y, Ogura K et al (2001) Helicobacter pylori activates the cyclin D1 gene through mitogen-activated protein kinase pathway in gastric cancer cells. Infect Immun 69:3965\u20133971","journal-title":"Infect Immun"},{"key":"7063_CR91","doi-asserted-by":"crossref","first-page":"6448","DOI":"10.3748\/wjg.v20.i21.6448","volume":"20","author":"TO Yau","year":"2014","unstructured":"Yau TO, Tang C-M, Yu J (2014) Epigenetic dysregulation in Epstein-Barr virus-associated gastric carcinoma: disease and treatments. World J Gastroenterol 20:6448\u20136456","journal-title":"World J Gastroenterol"},{"key":"7063_CR92","doi-asserted-by":"crossref","first-page":"e95993","DOI":"10.1371\/journal.pone.0095993","volume":"9","author":"LM Judd","year":"2014","unstructured":"Judd LM, Menheniott TR, Ling H, Jackson CB, Howlett M, Kalantzis A et al (2014) Inhibition of the JAK2\/STAT3 pathway reduces gastric cancer growth in vitro and in vivo. PLoS ONE 9:e95993","journal-title":"PLoS ONE"},{"key":"7063_CR93","doi-asserted-by":"crossref","first-page":"207","DOI":"10.3389\/fcimb.2019.00207","volume":"9","author":"G Sch\u00f6nrich","year":"2019","unstructured":"Sch\u00f6nrich G, Raftery MJ (2019) The PD-1\/PD-L1 axis and virus infections: a delicate balance. Front Cell Infect Microbiol 9:207","journal-title":"Front Cell Infect Microbiol"},{"key":"7063_CR94","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.gene.2015.11.010","volume":"576","author":"X Wang","year":"2016","unstructured":"Wang X, Zhang Y, Jiang L, Zhou F, Zhai H, Zhang M et al (2016) Interpreting the distinct and shared genetic characteristics between Epstein-Barr virus associated and non-associated gastric carcinoma. Gene 576:798\u2013806","journal-title":"Gene"},{"key":"7063_CR95","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.antiviral.2019.01.009","volume":"163","author":"AM Altman","year":"2019","unstructured":"Altman AM, Mahmud J, Nikolovska-Coleska Z, Chan G (2019) HCMV modulation of cellular PI3K\/AKT\/mTOR signaling: new opportunities for therapeutic intervention? Antiviral Res 163:82\u201390","journal-title":"Antiviral Res"},{"key":"7063_CR96","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/QCO.0000000000000248","volume":"29","author":"SL Servetas","year":"2016","unstructured":"Servetas SL, Bridge DR, Merrell DS (2016) Molecular mechanisms of gastric cancer initiation and progression by Helicobacter pylori. Curr Opin Infect Dis 29:304\u2013310","journal-title":"Curr Opin Infect Dis"},{"key":"7063_CR97","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/cncr.27724","volume":"119","author":"J Zhao","year":"2013","unstructured":"Zhao J, Liang Q, Cheung K-F, Kang W, Lung RWM, Tong JHM et al (2013) Genome-wide identification of Epstein-Barr virus-driven promoter methylation profiles of human genes in gastric cancer cells: EBV-driven methylation in gastric cancer. Cancer 119:304\u2013312","journal-title":"Cancer"},{"key":"7063_CR98","doi-asserted-by":"crossref","first-page":"e60315","DOI":"10.1371\/journal.pone.0060315","volume":"8","author":"J Baud","year":"2013","unstructured":"Baud J, Varon C, Chabas S, Chambonnier L, Darfeuille F, Staedel C (2013) Helicobacter pylori initiates a mesenchymal transition through ZEB1 in gastric epithelial cells. PLoS ONE 8:e60315","journal-title":"PLoS ONE"},{"key":"7063_CR99","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3892\/ijo.2017.4135","volume":"51","author":"WH Teo","year":"2017","unstructured":"Teo WH, Chen H-P, Huang JC, Chan Y-J (2017) Human cytomegalovirus infection enhances cell proliferation, migration and upregulation of EMT markers in colorectal cancer-derived stem cell-like cells. Int J Oncol 51:1415\u20131426","journal-title":"Int J Oncol"},{"key":"7063_CR100","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/978-3-319-91442-8_2","volume-title":"Small molecules in oncology","author":"M Voigtlaender","year":"2018","unstructured":"Voigtlaender M, Schneider-Merck T, Trepel M (2018) Lapatinib. In: Martens UM (ed) Small molecules in oncology. Springer International Publishing, Cham, pp 19\u201344"},{"key":"7063_CR101","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3816\/CCC.2011.n.008","volume":"10","author":"TW Dennie","year":"2011","unstructured":"Dennie TW, Fleming RA, Bowen CJ et al (2011) A phase I study of capecitabine, oxaliplatin, and lapatinib in metastatic or advanced solid tumors. Clin Colorectal Cancer 10:57\u201362","journal-title":"Clin Colorectal Cancer"},{"key":"7063_CR102","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.2165\/11205900-000000000-00000","volume":"70","author":"JD Croxtall","year":"2010","unstructured":"Croxtall JD, McKeage K (2010) Trastuzumab: in HER2-positive metastatic gastric cancer. Drugs 70:2259\u20132267","journal-title":"Drugs"},{"key":"7063_CR103","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3892\/ijmm.2016.2620","volume":"38","author":"M Katoh","year":"2016","unstructured":"Katoh M (2016) FGFR inhibitors: effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review). Int J Mol Med 38:3\u201315","journal-title":"Int J Mol Med"},{"key":"7063_CR104","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1158\/1078-0432.CCR-12-3898","volume":"19","author":"L Xie","year":"2013","unstructured":"Xie L, Su X, Zhang L, Yin X, Tang L, Zhang X et al (2013) FGFR2 gene amplification in gastric cancer predicts sensitivity to the selective FGFR inhibitor AZD4547. Clin Cancer Res 19:2572\u20132583","journal-title":"Clin Cancer Res"},{"key":"7063_CR105","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1136\/gutjnl-2011-301839","volume":"61","author":"N Deng","year":"2012","unstructured":"Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB et al (2012) A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut 61:673\u2013684","journal-title":"Gut"},{"key":"7063_CR106","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1007\/s10120-020-01088-y","volume":"23","author":"R Peng","year":"2020","unstructured":"Peng R, Chen Y, Wei L et al (2020) Resistance to FGFR1-targeted therapy leads to autophagy via TAK1\/AMPK activation in gastric cancer. Gastric Cancer 23:988\u20131002","journal-title":"Gastric Cancer"},{"key":"7063_CR107","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1158\/0008-5472.CAN-18-3539","volume":"80","author":"T Navas","year":"2020","unstructured":"Navas T, Kinders RJ, Lawrence SM et al (2020) Clinical evolution of epithelial-mesenchymal transition in human carcinomas. Cancer Res 80:304\u2013318","journal-title":"Cancer Res"},{"key":"7063_CR108","first-page":"1","volume":"17","author":"KS Bhullar","year":"2018","unstructured":"Bhullar KS, Lagar\u00f3n NO, McGowan EM, Parmar I, Jha A, Hubbard BP et al (2018) Kinase-targeted cancer therapies: progress, challenges and future directions. Mol Cancer BioMed Central 17:1\u201320","journal-title":"Mol Cancer BioMed Central"},{"key":"7063_CR109","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1177\/1078155216655474","volume":"23","author":"A Vennepureddy","year":"2017","unstructured":"Vennepureddy A, Singh P, Rastogi R, Atallah J, Terjanian T (2017) Evolution of ramucirumab in the treatment of cancer: a review of literature. J Oncol Pharm Pract 23:525\u2013539","journal-title":"J Oncol Pharm Pract"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-021-07063-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-021-07063-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-021-07063-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,23]],"date-time":"2023-01-23T01:42:53Z","timestamp":1674438173000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-021-07063-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,15]]},"references-count":109,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["7063"],"URL":"https:\/\/doi.org\/10.1007\/s11033-021-07063-9","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,15]]},"assertion":[{"value":"14 September 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors have no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}